Allergy

In a phase 3 NATRON trial presented at ACAAI 2025, Ogbogu discussed how benralizumab reduced flare in patients with hypereosinophilic syndrome.

At ACAAI 2025, Golden discussed how mild local reactions and expected systemic effects support the sublingual film’s strong safety profile in children.

Children achieved therapeutic epinephrine levels within 2 minutes on AQST-109 (Anaphylm), showing an early cardiovascular response similar to adults.

At ACAAI 2025, Gross outlined new food allergy ICD-10 codes, clarified documentation rules, and shared tips to help allergists prevent claim denials.

HCPLive spoke with Al Ali at ACAAI 2025 about a study comparing the safety of protocols for milk and peanut allergens.

Phase 3 LIBERTY AIMS data reveal significant reductions in nasal polyps, surgery, and steroid use in patients with AFRS, a challenging CRSwNP subtype.

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

At ACAAI 2025, Shaker dispels epinephrine myths, emphasizing that it is safe, effective, and underused in anaphylaxis care.

At ACAAI 2025, Shaker highlighted evolving therapies and real-world barriers that continue to limit optimal anaphylaxis management.

At ACAAI 2025, Durban breaks down natural allergy treatments and separates myths from evidence.

At ACAAI 2025, HCPLive spoke with Chovatiya on the OX40/OX40L pathway and what makes it an attractive therapeutic target over other established pathways.

A preview of 5 slated expert interviews and 5 late-breaking clinical trials to watch out for at ACAAI 2025.

This month in review spotlights 6 top allergy stories, from falling peanut allergy rates to intranasal steroid cream easing post-surgical rhinosinusitis.

Gabryszewski said new data confirm early introduction guidelines are working, showing real-world declines in peanut allergy.

New data show peanut allergy rates have dropped sharply since early introduction guidelines, reducing 27% and 43% after the 2015 and 2017 guidelines, respectively.

Study finds non-celiac gluten or wheat sensitivity is more common in women and linked to IBS, anxiety, and depression.

A study found that combining the eosinophil-to-lymphocyte ratio with CT-based sinus scores predicts smell recovery after CRSwNP surgery.

A real-world study found that using baked goods with sesame paste was safer than raw sesame seeds for oral immunotherapy.

Investigators estimate that replacing individually prescribed school-based devices with spare adrenaline autoinjectors could improve access for students.

Adults given an initial 0.5 mg intramuscular epinephrine dose were less likely to need further intervention than those receiving 0.3 mg, a study found.

In a recent study, a 30 mg maintenance dose significantly increased reaction thresholds and improved immune markers in children with peanut allergy.

A new study finds that rates of peanut and other IgE-mediated food allergies declined following the 2015 and 2017 early peanut introduction guidelines.

The study showed that infants consuming blueberries had lower IL-13, higher IL-10, and improved allergy symptom trajectories compared with placebo.

Most clinicians are not considering poor home air exposure when treating persistent asthma or airway disease, Raju explains. That may be making a difference in outcomes.

A new study found that adjunct omalizumab helped most patients safely continue honeybee venom immunotherapy after prior severe allergic reactions.